Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Retinoic acid receptor responder 2 pseudogene 7 (RARRES2P7) is classified as a processed pseudogene—a genomic DNA sequence that is similar to a functional gene (in this case, likely RARRES2/Chemerin), but contains mutations or lacks necessary elements for normal expression, precluding it from encoding a functional protein. Pseudogenes like RARRES2P7 are typically regarded as non-functional, though some pseudogenes have been shown to be transcribed and, in certain contexts, could have regulatory RNA functions, but no such evidence is established for RARRES2P7 specifically. As such, RARRES2P7 is not considered a biological or therapeutic target. Key point: RARRES2P7 is a non-coding pseudogene, not a functional receptor, enzyme, or protein, and should not be considered a drug target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Retinoic acid receptor responder 2 pseudogene 7 (RARRES2P7).